Reducing Exsanguination Via In Vivo Expandable Foam (REVIVE)

Reducing Exsanguination Via In-Vivo Expandable Foam (REVIVE)

Trauma is the leading cause of death in those under the age of 45, and the most common cause of preventable death after injury is bleeding.

Patients with severe bleeding inside the abdomen have a particularly high risk of dying. The only way to stop such bleeding is through surgery, and if the patient cannot be taken to an operating room in time, they die.

ResQFoam is a new investigational device, which aims to provide short-term control of abdominal bleeding, in the Emergency Department, before a surgeon can definitively stop the bleeding. ResQFoam comes as a liquid, which is injected into the abdominal cavity, and then forms a solid foam,which surrounds the abdominal organs and applies pressure to the site of injury, controlling the bleeding. The patient is then taken to surgery, the foam is removed, and the bleeding is stopped surgically.

This is first in human trial tested for the first time in patients and no prospective consent will be obtained due to the serious nature of the injury. The goal of the REVIVE study is to demonstrate the safety, effectiveness and benefit-risk profile of ResQFoam for the treatment of patients with life-threatening abdominal hemorrhage due to injury. The study is taking place in a small number of Level I Trauma centers. UAB is one of these centers.

Do you have any comments you would like to tell the researchers about this study?  We would value your feedback via the link below.  Your feedback will remain confidential.